Physician profile
Sophia T Chen
NPI 1033183934
$4,158.36
in general payments reported to CMS, 2019-2025
21 companies · $810 in 2025
The $810 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $233 · 2021: $186 · 2022: $753 · 2023: $762 · 2024: $929 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.10 | 2022-2025 | Lumigan |
| Alcon Vision LLC | $567.86 | 2019-2025 | Rocklatan, Eysuvis, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $505.24 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $470.60 | 2022-2025 | Tyrvaya, Ryzumvi, Tyrvaya |
| Sight Sciences, INC. | $432.43 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $327.21 | 2019-2021 | |
| Glaukos Corporation | $204.71 | 2022-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System, Idose Tr |
| Tarsus Pharmaceuticals, INC. | $203.96 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $179.68 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $145.06 | 2019-2024 | |
| Dompe US, INC. | $86.78 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $84.27 | 2023-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $65.17 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.31 | 2019-2020 | |
| Electromed, INC. | $55.03 | 2025 | Smartvest |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $48.91 | 2022 | |
| Integra Lifesciences Corporation | $46.05 | 2021 | |
| Stryker Corporation | $33.68 | 2025 | Na, Smartlock |
| Shire North American Group INC | $25.19 | 2019 | |
| Ivantis, INC | $25.02 | 2020 | |
| New World Medical,INC. | $12.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sophia Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.